Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Friday, August 21, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Gossamer Bio has announced a significant private placement financing of up to $250 million, which includes $150 million in committed capital. This funding is intended to support the development of seralutinib, a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, as it progresses towards potential FDA approval.
Market Sentiment Analysis
POSITIVE FACTORS
Secured up to $250 million in structured private placement.
Includes $150 million of committed capital.
Funding aims to support seralutinib through potential FDA approval.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Full Press Release Details
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing
Frequently Asked Questions
What is the purpose of Gossamer Bio's funding?
The funding aims to support the development of seralutinib for pulmonary arterial hypertension and related conditions.
How much capital has Gossamer Bio secured?
Gossamer Bio has secured up to $250 million, including $150 million of committed capital.
What conditions does seralutinib target?
Seralutinib is being developed for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Who are the investors in this private placement?
The private placement involves certain new and existing institutional investors.